



Infl ammation and haemostasis are interrelated pathophysiologic processes that considerably aff ect each other. In this bidirectional relationship, 
infl ammation leads to activation of the haemostatic system that in turn also considerably infl uences infl ammatory activity. Such, the haemostatic 
system acts in concert with the infl ammatory cascade creating an infl ammation-haemostasis cycle in which each activated process promotes the 
other and the two systems function in a positive feedback loop. The extensive crosstalk between immune and haemostatic systems occurs at level 
of all components of the haemostatic system including vascular endothelial cells, platelets, plasma coagulation cascade, physiologic anticoagulants 
and fi brinolytic activity. During infl ammatory response, infl ammatory mediators, in particular proinfl ammatory cytokines, play a central role in the 
eff ects on haemostatic system by triggering its disturbance in a number of mechanisms including endothelial cell dysfunction, increased platelet 
reactivity, activation of the plasma coagulation cascade, impaired function of physiologic anticoagulants and suppressed fi brinolytic activity.
The two examples of pathophysiologic processes in which the tight interdependent relationship between infl ammation and haemostasis consi-
derably contribute to the pathogenesis and/or progression of disease are systemic infl ammatory response to infection or sepsis and acute arterial 
thrombosis as a consequence of ruptured atherosclerotic plaque. Close links between infl ammation and haemostasis help explain the prothrombotic 
tendency in these two clinical conditions in which infl ammation shifts the haemostatic activity towards procoagulant state by the ability of proinfl a-
mmatory mediators to activate coagulation system and to inhibit anticoagulant and fi brinolytic activities.
This review summarizes the current knowledge of the complex interactions in the bidirectional relationship between infl ammation and haemostasis.
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Infl ammation and haemostasis are tightly interre-
lated pathophysiologic processes that considera-
bly aff ect each other. In this bidirectional relation-
ship, infl ammation leads to activation of the hae-
mostatic system that in turn also considerably in-
fl uences infl ammatory activity (1,2). Close interac-
tion between immune and haemostatic systems is 
an attempt to restore normal tissue function fol-
lowing injury. Local activation of the haemostatic 
system is an essential part of the host defence in 
both infectious and non-infectious infl ammatory 
states. However, an exaggerated and insuffi  ciently 
controlled haemostatic activity induced by infl am-
mation may appreciably contribute to disease se-
verity. The two examples of clinical conditions in 
which the tight interdependent relationship be-
tween infl ammation and haemostasis considera-
bly contribute to the pathogenesis and/or progres-
sion of disease are systemic infl ammatory response 
to infection or sepsis and acute arterial thrombosis 
as a consequence of ruptured atherosclerotic 
plaque. Close links between infl ammation and 
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haemostasis help explain the prothrombotic ten-
dency in these two clinical conditions. Infl amma-
tion shifts the haemostatic activity towards proco-
agulant state by the ability of proinfl ammatory 
mediators to activate coagulation system and to 
inhibit anticoagulant and fi brinolytic activities. 
Once the activation of haemostatic system occurs 
in infl ammatory states, amplifi cation of the hae-
mostatic disorder can result in thrombosis and or-
gan damage. In turn, uncontrolled activation of 
the haemostatic system can also amplify the initial 
infl ammatory response thus causing additional or-
gan injury. Such, the haemostatic system acts in 
concert with the infl ammatory cascade creating 
an infl ammation-haemostasis cycle in which each 
activated process promotes the other and the two 
systems function in a positive feedback loop.
The goal of infl ammation is to restore the integrity 
of threatened or damaged tissues because of inju-
ry or infectious pathogens. On the other hand, 
haemostasis is a physiological defence mechanism 
to stop bleeding due to vessel wall damage (3). Ac-
tivated by vessel wall injury, the haemostatic sys-
tem consists of a complex network of individual 
components. Vascular endothelial cells (ECs) and 
platelets constitute primary haemostasis resulting 
with a formation of platelet clot. This process is fol-
lowed by an activation of the plasma coagulation 
cascade, so called secondary haemostasis that in-
duces a formation of a fi brin clot. The net result of 
the haemostatic activation is stable platelet-fi brin 
clot. These processes are fi rmly regulated by physi-
ologic anticoagulant mechanisms that keep acti-
vation of the coagulation system under control 
and by fi brinolytic system which is responsible for 
degradation of the platelet-fi brin clot which has 
fulfi lled its function (4).
In recent years, various molecular mechanisms 
that play a role in the bidirectional relationship be-
tween infl ammation and haemostasis have been 
intensively investigated and elucidated. This re-
view summarizes the current knowledge of the 
complex interactions in the bidirectional relation-
ship between these two interrelated processes.
Mechanisms by which infl ammation 
induces disturbance of the haemostatic 
system
The extensive crosstalk between immune and hae-
mostatic systems occurs at the level of all compo-
nents of the haemostatic system including vascu-
lar ECs, platelets, plasma coagulation cascade, 
physiologic anticoagulant pathways and fi brino-
lytic activity. During an infl ammatory response, in-
fl ammatory mediators, in particular proinfl amma-
tory cytokines, play a central role in the eff ects on 
haemostatic system (5,6). The main mediators of 
infl ammation-induced activation of the haemo-
static system are proinfl ammatory cytokines tu-
mour necrosis factor-alpha (TNF-α), interleukin 1 
(IL-1) and interleukin 6 (IL-6) (7). Infl ammatory me-
diators trigger disturbance of the haemostatic sys-
tem in a number of mechanisms including en-
dothelial cell dysfunction, increased platelet acti-
vation, tissue factor (TF) mediated activation of the 
plasma coagulation cascade, impaired function of 
physiologic anticoagulant pathways and sup-
pressed fi brinolytic activity (Figure 1).
Dysfunction of vascular endothelial cells
Vascular ECs are actively involved in haemostasis. 
In physiological conditions, intact endothelium 
functions as an antithrombotic surface thus pre-
venting inappropriate activation of coagulation. 
ECs are the main producer of components with 
proinfl ammatory, procoagulant and antifi brinolyt-
ic activities, as well as of those with the opposite 














FIGURE 1. Mechanisms of infl ammation-induced disturbance of the haemostatic system.
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By binding thrombin enables 
activation of the protein C (PC)
Endothelial protein C 
receptor (EPCR)
By binding protein C (PC), augments 
its activation into activated protein C 
(APC) at the cell surface.
It is considered that it  also has an 
important role in anti-infl ammatory 
actions of the APC
Tissue factor pathway 
inhibitor (TFPI)
Inhibitor of tissue factor-FVIIa 
complex
Prostacyclin (PGI2) Vasodilatator, inhibitor of platelet aggregation and leukocyte adhesion
Nitric oxide (NO) Vasodilatator, inhibitor of platelet aggregation and leukocyte adhesion
Thromboxane A2
(TXA2)
Vasoconstrictor, stimulates secretion 
from the platelet granules (agonist 
for platelet aggregation)
Von Willebrand factor 
(vWF)
Primary haemostasis: platelet 
adhesion
Secondary haemostasis: carrier 
protein for coagulation factor VIII
Platelet-activating
factor (PAF)








Inhibition of fi brinolysis by binding 
plasminogen activators t-PA and 
urokinase plasminogen activator (uPA)
Vascular cell adhesion 
molecule-1 (VCAM-1)




Mediates leukocyte adhesion and 
endothelial transmigration
P-selectin
Mediates cell interactions between 
ECs and leukocytes (enables 
recruitment of leukocytes to the site 
of injury during infl ammation)
E-selectin
Mediates cell interactions between 
ECs and leukocytes (enables 
recruitment of leukocytes to the site 
of injury during infl ammation)
Heparan sulphate
Physiologic heparin-like cofactor 
for anticoagulant activity of 
antithrombin
Tissue factor (TF) Activation of plasma coagulation cascade
TABLE 1. Integral components of the vascular endothelial cells.
actions, i.e. anticoagulant, anti-infl ammatory and 
profi brinolytic properties (Table 1). All these com-
ponents are essential in maintaining a physiologi-
cal balance involved in the regulation of the hae-
mostatic system.
Irrespective of its aetiology, infl ammation leads to 
an imbalance between proinfl ammatory and pro-
coagulant and anti-infl ammatory and anticoagu-
lant properties of the endothelium thus contribut-
ing to disturbance of the haemostatic system. 
Once activated or injured, ECs secrete into the lo-
cal environment mostly procoagulant or antifi bri-
nolytic components, such as von Willebrand factor 
(vWF), thromboxane A2 (TXA2) or plasminogen 
activator inhibitor-1 (PAI-1)) while the expression 
or secretion of components with anticoagulant 
and profi brinolytic properties is signifi cantly re-
duced (Figure 2). In addition, activated ECs can ex-
press at their surface tissue factor (TF) and adhe-
sion molecules such as P- and E-selectins, vascular 
cell adhesion molecule-1 (VCAM-1) and intercellu-
lar cell adhesion molecule-1 (ICAM-1) (Figure 2). 
Adhesion molecules have important role in medi-
ating interaction of neutrophils and platelets with 
endothelium, thus also promoting the infl amma-
tory and haemostatic responses. As a result of dis-
turbed balance due to infl ammation, the function 
of ECs shifts from an anticoagulant, anti-infl amma-
tory and vasodilatatory phenotype to a proinfl am-
matory and procoagulant state. Such, in infl amma-
tory states the endothelium serves as an impor-
tant interface between infl ammation and inappro-























FIGURE 2. Endothelial cell dysfunction induced by infl amma-
tion. EC - endothelial cell; TXA2 – thromboxane A2; PAF – plate-
let-activating factor; vWF – von Willebrand factor; PAI-1 – plas-
minogen activator inhibitor-1; VCAM-1 – vascular cell adhesion 
molecule-1; ICAM-1 – intercellular adhesion molecule-1; TF – tis-
sue factor; EPCR – endothelial protein C receptor; TM – throm-
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Proinfl ammatory cytokines TNF-α, IL-1 and IL-6 are 
crucial in mediating the procoagulant eff ects of 
dysfunctional ECs. Vascular ECs respond to the cy-
tokines expressed and released by infl ammatory 
cells, such as activated leukocytes, but can also re-
lease cytokines themselves thereby amplifying the 
haemostatic response in infl ammatory states (9).
ECs play an important role in all mechanisms that 
contribute to infl ammation-induced disturbance 
of the haemostatic system, including activation of 
platelets and other infl ammatory cells (in particu-
lar leukocytes), TF-mediated initiation and regula-
tion of thrombin generation, as well as impaired 
function of physiologic anticoagulants and sup-
pressed fi brinolytic activity. Physiologic inhibitors 
of coagulation, such as protein C (PC) system and 
tissue factor pathway inhibitor (TFPI) are connect-
ed to the endothelium, so that ECs play a key role 
in maintaining the function of these anticoagulant 
mechanisms. Also, as the main producer of fi brino-
lytic activator, i.e. tissue plasminogen activator 
(tPA) and inhibitor (PAI-1), ECs also have an obvious 
role in suppressed fi brinolytic activity in infl amma-
tory states. All these changes of ECs lead to the ex-
posure of procoagulant components to blood and 
contribute to a prothrombotic state in infl amma-
tory states.
Platelet activation induced by 
infl ammation
Beside of an important role in haemostasis, plate-
lets also play a relevant function in infl ammation 
acting as proinfl ammatory cells (10). In physiologi-
cal conditions, platelets circulate in a resting state, 
protected from activation by inhibitory mediators, 
such as nitric oxide (NO) and prostacyclin (PGI2) re-
leased from intact ECs. Numerous factors promote 
platelet activation during infl ammatory response. 
Such, EC dysfunction leads to increased platelet 
reactivity due to its elevated production of TXA2 
and vWF and decreased production of PGI2. Upon 
vessel wall injury platelets rapidly adhere to the 
exposed subendothelial matrix. This process is me-
diated by several cellular receptors as well as vari-
ous adhesive and regulatory proteins present on 
platelets or ECs thus allowing platelet-vessel wall 
interaction and subsequent thrombus formation 
(11). Additionally, in the setting of infl ammation-
induced activation of haemostasis, platelets can 
be directly activated with infl ammatory mediators 
such as proinfl ammatory cytokines or platelet-ac-
tivating factor (PAF) in case of both non-infectious 
and infectious infl ammatory states (12) or with en-
dotoxin in case of sepsis. Further, thrombin gener-
ated by activated coagulation cascade is one of 

























FIGURE 3. Platelet activation induced by infl ammation. EC – endothelial cell; TXA2 – thromboxane A2; vWF – von Willebrand factor; 
PGI2 – prostacyclin; PAF – platelet activating factor; GPIIb/IIIa – glycoprotein complex IIb/IIIa; PDGF – platelet derived growth factor; 
TGF-β - transforming growth factor-beta; EGF – epidermal growth factor; IL-1β - interleukin 1beta; PF-4 – platelet factor 4; RANTES – 
CCL5 chemokine; PAI-1 – plasminogen activator inhibitor 1; TF – tissue factor.
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Upon activation, platelets undergo shape change 
from a disc-shaped cell into a spherical-shaped cell 
and express at their surface or secrete into the lo-
cal environment a number of proinfl ammatory 
and procoagulant substances (13), such as adhe-
sion molecules, growth factors, cytokines and 
chemokines and certain coagulation factors and 
fi brinolytic inhibitor PAI-1 (Figure 3). Additionally, 
platelets may generate procoagulant rich particles, 
called microparticles (MPs), a circulating cell frag-
ments derived from activated or apoptotic cells. 
MPs contain negatively charged phospholipids es-
sential for coagulation reactions and express TF on 
their surface (14,15) and thus contribute to the pro-
thrombotic state (Figure 3).
Individual platelet mediators modulate functions 
of other platelets, leukocytes and ECs. As an exam-
ple, activated platelets secrete IL-1β, which is a ma-
jor activator of ECs. This interaction of platelets 
with ECs results with secretion of IL-6 and mono-
cyte chemotactic protein 1 (MCP-1) from ECs, as 
well as with the expression of adhesion molecules 
E-selectin, VCAM-1 and ICAM-1 on ECs (16). Fur-
ther, interaction of platelets with neutrophils pro-
motes the recruitment of neutrophils into infl am-
matory tissue thus directly participating in the 
host defence (17). Interaction of platelets with in-
fl ammatory cells such as leukocytes and ECs is 
mainly mediated through platelet P-selectin, a cell 
adhesion receptor localized in platelet’s alpha-
granules (18,19). Upon platelet activation, P-selec-
tin is rapidly translocated to the cell surface and 
serves as the receptor for its natural ligand, P-se-
lectin glycoprotein ligand (PSGL-1) expressed on 
neutrophils, monocytes and ECs thus mediating 
platelet-leukocyte and platelet-EC interactions 
(18,20). Cellular interaction via P-selectin markedly 
enhances the production of proinfl ammatory cy-
tokines and chemokines in neutrophils and mono-
nuclear cells and increases the expression of adhe-
sion molecules and TF on both leukocytes and ECs 
(5,19). The molecular mechanism of this eff ect re-
lies on nuclear factor kappa B (NF-κB) activation 
induced by binding of activated platelets to neu-
trophils, mononuclear cells and ECs (13).
Activation of the plasma coagulation 
cascade in infl ammation
The main mechanism of plasma coagulation cas-
cade activation in infl ammation is mediated by TF 
(21-23). TF is a transmembrane protein constitu-
tively expressed by a variety of cell types including 
circulatory blood cells and ECs. Also, it is present in 
all blood-tissue barriers, such as adventitial layer of 
the vessel wall, so that coagulation can be initiated 
quickly once the endothelial barrier has been dis-
rupted (24,25). However, in contrast to other coag-
ulation factors, TF is normally not in direct contact 
with blood. Such, circulatory blood cells and ECs 
do not express TF under normal physiological con-
ditions. However, when the integrity of the vessel 
wall is disrupted or if circulatory blood cells or ECs 
start to express TF in response to various proin-
fl ammatory stimuli, such as proinfl ammatory cy-
tokines (TNF-α, IL-1 and IL-6) or endotoxin, TF ex-
pression is induced in diff erent cell types including 
leukocytes (predominantly monocytes and mac-
rophages) and ECs. It enables that TF comes into 
direct contact with blood (Figure 4). On exposure 
to blood, TF binds to FVII and the complex TF-FVI-
Ia initiates the activation of the coagulation cas-
cade through the conversion of coagulation fac-
tors FIX and FX into activated forms (FIXa and FXa) 
Induction of tissue factor expression on different cell types


















FIGURE 4. Tissue factor-mediated activation of coagulation in-
duced by infl ammation. TF – tissue factor; ECs – endothelial 
cells; PL – phospholipids.
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thereby generating thrombin (FIIa) whose key func-
tion is to convert fi brinogen to fi brin (Figure 4).
Thrombin generated by activated coagulation cas-
cade is a multifunctional molecule with many 
physiological functions. Such, thrombin has multi-
level procoagulant activity. Besides it converts fi -
brinogen to fi brin, thrombin itself is one of the 
strongest platelet activators and also it is involved 
in feedback activation of coagulation by activating 
coagulation factors V, VIII, XI and XIII. Additionally, 
thrombin has relevant proinfl ammatory activity 
such as activation of infl ammatory cells (leuko-
cytes and ECs) with consequent increased produc-
tion of infl ammatory mediators and increased leu-
kocytes adhesion and chemotaxis. Thrombin is an 
important regulator of cellular activation through 
binding to the protease-activated receptors (PARs) 
expressed on platelets, leukocytes and ECs. This 
represents the main mechanism by which activat-
ed haemostatic system augments initial infl amma-
tory response, as it will be discussed later.
Additionally, activation of the coagulation cascade 
is markedly facilitated if a suitable phospholipid 
surface is available. Namely, coagulation reactions 
occur on membrane surfaces that contain nega-
tively charged phospholipids. In normal physio-
logical conditions, there are little negatively 
charged phospholipids exposed to the blood. 
However, both activated platelets and ECs trans-
port their negatively charged phospholipids to the 
surface thus providing a phospholipid rich surface 
on their membrane. The phospholipid rich surface 
has an important role for assembly of complexes 
of activated coagulation factors. The presence of 
such a surface may accelerate several-fold the gen-
eration of thrombin and render the coagulation 
system less susceptible to fl uid-phase protease in-
hibitors.
Physiologic anticoagulants in 
infl ammation
The three major anticoagulant mechanisms in-
volved in the regulation of coagulation activation 
are antithrombin (AT), PC system and tissue factor 
pathway inhibitor (TFPI). Antithrombin is the main 
inhibitor of thrombin, FXa and FIXa. PC pathway 
proteolytically cleaves activated coagulation co-
factors FVa and FVIIIa. TFPI is the main inhibitor of 
the TF-FVIIa complex (Figure 5). The main function 
of these coagulation inhibitors is to prevent blood 
clotting under physiological conditions and to 
slow down the activated coagulation cascade af-
ter vascular injury.
Normal level and function of physiologic anticoag-
ulants appears to be important in the defence 
against haemostatic abnormalities in infl ammato-
ry states. There is increasing evidence that physio-
logic inhibitors of coagulation besides their antico-
agulant actions also have important anti-infl am-
matory functions (26). However, the function of all 
three pathways can be impaired during infl amma-
tion-induced disturbance of the haemostatic sys-
tem. It represents an important mechanism of pro-
coagulant state in infl ammation (27,28).
Fibrinogen Fibrin
IIa (Thrombin)
Antithrombin Xa  +  Va
IXa  +  VIIIa
II






FIGURE 5. The three major physiological anticoagulant mecha-
nisms: antithrombin, protein C system and tissue factor path-
way inhibitor.
Antithrombin
In infl ammatory states, the function of AT can be 
impaired as a result of increased consumption (due 
to activated coagulation cascade), decreased syn-
thesis (as a result of a negative acute phase re-
sponse) and increased degradation by proteolytic 
enzymes (elastase from activated neutrophils). Ad-
ditionally, proinfl ammatory cytokines can cause 
reduced synthesis of glycosaminoglycans (GAGs), 
such as heparan sulphate on the endothelial sur-
face, which also may contribute to the impaired AT 
function since endogenous GAGs act as physiolog-
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ic heparin-like cofactors thus promoting anticoag-
ulant activity of AT (29).
Some of the anti-infl ammatory properties of AT 
are mediated by its anticoagulant actions in the 
coagulation cascade. By binding thrombin, AT con-
tributes to reduced activation of proinfl ammatory 
cells (leukocytes, ECs and platelets). Further, in-
creasing evidences suggest that AT possesses anti-
infl ammatory action independent of its anticoagu-
lant activity. Such, AT directly interacts with leuko-
cytes by binding to their receptors thus blocking 
the interaction of leukocytes with ECs, i.e. leukocyte 
migration and adhesion to ECs (30). Additionally, AT 
induces release of PGI2 from ECs. PGI2 acts as an in-
hibitor of platelet aggregation and blocks neu-
trophil adhering to blood vessels thus contributing 
to decreased production of proinfl ammatory cy-
tokines and chemokines in neutrophils and ECs (31).
Protein C system
Among the three key natural anticoagulant mech-
anisms, the PC system appears to be the most im-
portant in regulating infl ammatory response and 
at the same time the most negatively infl uenced 
by infl ammatory states. Under physiological con-
ditions, PC is activated by thrombin bound to en-
dothelial cell membrane associated protein throm-
bomodulin (TM). Activated protein C (APC) with its 
cofactor protein S (PS) inactivates FVa and FVIIIa. 
There is increasing evidence that PC system also 
has important functions in modulating infl amma-
tory response (32,33), by its anti-infl ammatory and 
profi brinolytic activities (34,35). Anti-infl ammatory 
actions of APC include inhibition of cytokine 
(TNF-α, IL-1, IL-6) production by monocytes/mac-
rophages (36), inhibition of chemotaxis and adhe-
sion of leukocytes to endothelium and suppres-
sion of NF-κB transcription (34). It is considered 
that anti-infl ammatory eff ects of APC are mediat-
ed by the endothelial protein C receptor (EPCR) 
(37). Binding of APC to EPCR infl uences gene ex-
pression profi les of cells by blocking NF-κB nuclear 
translocation. This results with limited production 
of proinfl ammatory cytokines and expression of 
cell surface adhesion molecules in ECs (38). Fur-
ther, APC has profi brinolytic action mediated by 
neutralization of PAI-1 activity. In addition to these 
anti-infl ammatory actions of APC, particular com-
ponents of the PC system can also contribute to 
attenuated infl ammatory response. Besides an es-
sential role of TM in PC system activation, it also 
suppresses infl ammation by direct and indirect 
mechanisms (39). Thrombomodulin-mediated 
binding of thrombin attenuates proinfl ammatory 
eff ects of thrombin, such as platelet activation, 
chemotaction of monocytes and neutrophils, up-
regulation of leukocyte adhesion molecules and 
activation of infl ammatory cells by binding to PARs 
(40). Also, by binding to thrombin, TM blocks its 
procoagulant action i.e., ability to clot fi brinogen. 
Additionally, the thrombin-TM complex activates 
thrombin-activatable fi brinolysis inhibitor (TAFI), 
an important inhibitor of fi brinolysis but also a 
molecule responsible for inactivation of comple-
ment component C5a, an anaphylatoxin created 
during complement activation (41). Considering 
that TM is abundantly present in the microcircula-
tion, TAFI-mediated inactivation of C5a would be 
expected to protect against complement-mediat-
ed injury of the microvasculature (2).
As in case of AT, function of the PC system may be 
impaired because of decreased synthesis or in-
creased consumption and degradation in infl am-
matory states. Furthermore, downregulation of TM 
and EPCR at the endothelial surface caused by 
proinfl ammatory cytokines (TNF-α, IL-1β) and neu-
trophil elastase from activated neutrophils may 
further negatively aff ect function of the PC system 
(42). In addition, increased plasma levels of C4b-
binding protein (C4B-BP) as an acute phase reac-
tant can result in a relative PS defi ciency due to 
decreased levels of free PS, which further can con-
tribute to a procoagulant state (6).
Impairment of the PC system appears to play an 
important role in the pathogenesis of sepsis and 
associated organ dysfunction (43,44), as it will be 
discussed later in the text.
Tissue factor pathway inhibitor (TFPI)
The third physiological anticoagulant mechanism 
is TFPI (45), a serine protease inhibitor attached to 
the endothelium via GAGs and secreted by ECs. As 
in case of AT, proinfl ammatory cytokines can cause 
reduced synthesis of GAGs on the endothelial sur-
face, which may aff ect the function of TFPI. How-
ever, relatively little is known about the impact of 
Biochemia Medica 2012;22(1):49–62
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infl ammation on TFPI function. Its role in the regu-
lation of infl ammation-induced activation of hae-
mostasis is not completely clear mostly because 
the majority of TFPI is associated with the vessel 
endothelium and direct assays of endogenous 
TFPI activity in vivo are not routinely available. Be-
cause of that it makes very diffi  cult to assess 
whether this anticoagulant pathway is modulated 
by infl ammation (46). Clinical experiments showed 
that administration of recombinant TFPI blocked 
infl ammation-induced thrombin generation in hu-
mans (47,48). These results suggest that high con-
centrations of TFPI are capable of modulating TF-
mediated activation of coagulation. However, the 
endogenous concentration of TFPI is considered 
not to be capable of regulating coagulation activa-
tion during infl ammation.
Fibrinolytic system
Haemostasis is further controlled by the fi brinolyt-
ic system, in which the key enzyme, plasmin de-
grades fi brin clot. Plasmin is generated from plas-
minogen by activators such as tPA and urokinase 
plasminogen activator (uPA). The main inhibitor of 
these plasminogen activators is PAI-1. Binding to 
plasminogen activators, PAI-1 causes their inacti-
vation thus suppressing the fi brinolytic activity.
Inhibition of the fi brinolytic system is another im-
portant component in the haemostatic disorder 
during infl ammatory states. The initial acute fi bri-
nolytic response in infl ammatory states is a tran-
sient increase in fi brinolytic activation mediated 
by the immediate release of tPA from vascular ECs. 
However, this increased plasminogen activation is 
followed by delayed but sustained increase in the 
main fi brinolytic inhibitor PAI-1. It results with sig-
nifi cant suppression of fi brinolytic activity and 
subsequent inadequate fi brin removal. The main 
regulators of PAI-1 activity are proinfl ammatory 
cytokines TNF-α and IL-1β (49), which induce the 
production of PAI-1 in vascular ECs (Figure 6). Fur-
ther, platelet alpha granules also contain large 
amounts of PAI-1 and release it upon their activa-
tion. This may further increase the levels of PAI-1 
and contribute to the fi brinolytic suppression in 
infl ammatory states. Additionally, dysfunction of 
ECs induced by infl ammation may also result with 
delayed but sustained decreased production of 
tPA (Figure 6).
Individual fi brinolytic components may also mod-
ulate the infl ammatory response by their eff ect on 
infl ammatory cell recruitment and migration. In 
particular, uPA and its receptor urokinase plas-
minogen activator receptor (uPAR) are involved in 
these processes. Such, uPAR expressed on leuko-
cytes mediates leukocyte adhesion to the vascular 












FIGURE 6. Mechanisms of suppressed fi brinolytic activity in-
duced by infl ammation. uPA – urokinase plasminogen activa-
tor; tPA – tissue plasminogen activator; PAI-1 – plasminogen ac-
tivator inhibitor-1; FDP – fi brin degradation products.
Mechanisms by which activated 
haemostatic system infl uences 
infl ammatory response
The communication between infl ammation and 
haemostasis is a bidirectional process, so activated 
haemostatic system also considerably modulates 
infl ammatory activity. Individual components of 
the activated haemostatic system, such as activat-
ed coagulation factors thrombin, FXa and TF-FVIIa 
complex can directly stimulate cells involved in in-
fl ammatory response (platelets, leukocytes and 
ECs) with consequent increased production of 
proinfl ammatory mediators by these cells. The key 
mechanism by which activated coagulation fac-
tors augment infl ammatory response is by their 
binding to PARs. The PAR family of receptors con-
sists of four members, PAR-1 to PAR-4, which are 
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localized on diff erent cell types such as ECs, leuko-
cytes, platelets, fi broblasts and smooth muscle 
cells. (24,51). These receptors serve as their own 
ligand, so that proteolytic cleavage of PAR by an 
activated coagulation factor activates the same re-
ceptor. Coagulation proteases activate PARs in a 
common way. The receptor is proteolitically 
cleaved at a specifi c site within its intracellular N-
terminus. It leads to exposure a new terminus that 
serves as a ligand for the same receptor and results 
with a transmembrane signal transduction and con-
sequent increased infl ammatory response (7). PAR-1, 
3 and 4 are thrombin receptors, while PAR-2 recep-
tor can be activated by the TF-FVIIa complex or FXa. 
Binding of an activated coagulation factor to the in-
dividual PAR receptor results in upregulation of in-
fl ammatory responses by inducing the production 
of proinfl ammatory mediators, such as cytokines, 
chemokines, growth factors and cell adhesion mol-
ecules. Such, PARs seem to play an important role in 
linking infl ammation and haemostasis (52).
Activated platelets also play an important role in 
enhanced infl ammatory response, in particular in 
chronic infl ammatory states such as atherosclero-
sis, as it will be discussed in the next section.
Further, fi brinogen as well as fi brin generated by 
activated coagulation cascade also mediates cellu-
lar activation in infl ammation. Such, fi brinogen and 
fi brin are capable of recruiting and activating leuko-
cytes by binding to the specifi c receptors, such as 
toll-like receptors (TLR) expressed at the surface of 
infl ammatory cells (53,54). Both fi brinogen and fi -
brin stimulate the expression of proinfl ammatory 
cytokines (TNF-α, IL-1β) on monocytes and chem-
okines (IL-8, MCP-1) on ECs and fi broblasts (55).
Specifi c features of haemostatic disorder 
induced by infl ammation in acute arterial 
thrombosis and systemic infl ammatory 
response to infection (sepsis)
Atherosclerosis and consequent acute arterial 
thrombosis and sepsis represent the examples of 
the two clinical conditions in which close relation-
ship between infl ammation and haemostasis con-
siderably contributes to disease severity. Because, 
in the next section of this article the most impor-
tant features in the bidirectional relationship be-
tween infl ammation and haemostasis in these two 
pathophysiological states will be discussed.
Relationship between infl ammation and
haemostasis in acute arterial thrombosis
Atherosclerosis is a chronic infl ammatory process 
(56) in which thrombus formation on a ruptured 
atherosclerotic plaque is the pathological basis of 
an acute arterial thrombotic event such as myocar-
dial infarction (10,57). Infl ammation plays an im-
portant role in atherosclerotic process, including 
fatty streak formation, plaque destabilization and 
subsequent thrombosis (58,59). However, the 
mechanisms of arterial thrombosis involve not 
only infl ammation, but rather a combination of in-
fl ammatory and prothrombotic factors that con-
siderably aff ect each other (5,60). Such, platelets 
have an important role in the pathogenesis of ar-
terial thrombosis including atherosclerotic plaque 
formation as well as its progression to acute throm-
botic event (16,60). It has been shown that plate-
lets rapidly adhere to the injured endothelium (61). 
In an atherosclerotic process, erosion of the vessel 
intimae exposes subendothelial collagen to the 
blood, which causes platelet adhesion, activation 
and subsequent aggregation (62). Once recruited 
to the atherosclerotic lesion, platelets become ac-
tivated and express proinfl ammatory molecules 
that can additionally promote chemoattraction of 
leukocytes (PAF, macrophage infl ammatory pro-
tein-1 (MIP-1)), stimulation of smooth muscle cells, 
fi broblast proliferation (PDGF, serotonin, TGF-β) 
and collagen synthesis. Additionally, activated 
platelets release proinfl ammatory cytokines (CD40 
ligand, IL-1β) and chemokines (platelet factor-4 
(PF-4), RANTES) which support monocyte recruit-
ment to atherosclerotic plaques. Platelet adhesion 
to the subendothelial surface supports leukocyte 
rolling and extravasation through interaction of 
platelet P-selectin with PSGL-1 receptor expressed 
on leukocytes. Also, as it has already been told, ac-
tivated platelets contain procoagulant molecules 
that directly contribute to activation of the hae-
mostatic system.
Further, expression of the procoagulant material, 
in particular TF, by infl ammatory cells in the unsta-
ble or ruptured plaque acts as one of the main ac-
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tivators of the coagulation cascade (63). Induced 
expression of TF on ECs, monocytes and smooth 
muscle cells in atherosclerotic plaques is mostly 
mediated by sustained increased levels of proin-
fl ammatory cytokines TNF-α and IL-1β (64). Since 
these cells respond to infl ammatory signals within 
the plaque, its rupture promotes increased cell ex-
pression of TF (60,63). It has been shown that 
mononuclear cells in atherosclerotic plaque ex-
press much more TF than native mononuclear cells 
in the circulation due to sustained exposure to 
proinfl ammatory mediators in the plaque, such as 
cytokines (IL-1, IL-6, TNF-α) and chemokines (PDGF, 
MCP-1). It is apparent that circulating monocytes 
represent one of the principal players in the cross-
talk between infl ammation and activated coagula-
tion system in an atherosclerotic process.
At the same time with an activation of the coagu-
lation system in a progressive atherosclerotic proc-
ess, there is also a reduced function of anticoagu-
lant PC system mostly due to downregulated TM 
and EPCR expression in ECs overlying a plaque in 
coronary arteries (42). Downregulation of these 
two important components of the PC system is 
mostly mediated by sustained increased levels of 
proinfl ammatory cytokines TNF-α and IL-1β. It may 
result with decreased PC activation and potentially 
lead to more extensive thrombin generation at the 
site of the atherosclerotic lesion. It appears that pa-
tients with heterozygous mutation in the TM gene 
have a higher risk of myocardial infarction (65). As it 
has already been told, besides of its anticoagulant 
activity, TM also has anti-infl ammatory actions.
Additionally, sustained increased levels of proin-
fl ammatory cytokines TNF-α and IL-1β can cause 
increased production of PAI-1 in ECs within the 
plaque. It contributes to suppressed fi brinolytic 
activity in atherosclerotic process.
Relationship between infl ammation and
haemostasis in sepsis
Another example of close interaction between im-
mune and haemostatic system is obvious in sepsis. 
Sepsis is a clinical syndrome characterized by an 
excessive systemic host response to infection re-
sulting with an uncontrolled activation of infl am-
matory response. Since the immune and haemo-
static systems are tightly linked, an excessive in-
fl ammatory response can also lead to systemic ac-
tivation of the haemostatic system. In fact, local 
activation of the coagulation in septic patients is 
an integral component of the host defence as an 
attempt to eradicate the invading microorganism. 
However, an exaggerated response to infection 
can lead to a situation in which systemic activation 
of the haemostatic system itself contributes to dis-
ease severity, causing a syndrome known as dis-
seminated intravascular coagulation (DIC) (24,66). 
Patients with severe form of DIC may clinically 
present with manifest thromboembolic disease or 
clinically less apparent microvascular fi brin deposi-
tion that contribute to the multiple organ dysfunc-
tion (67,68). With the progression of sepsis, coagu-
lopathy becomes increasingly more severe. Pro-
gression of the haemostatic disorder in sepsis re-
sults in the widespread formation of fi brin clots, 
microvascular occlusion and reduced oxygen de-
livery to cells and tissues with subsequent organ 
dysfunction (67). DIC has been shown to be an im-
portant independent predictor of organ failure 
and mortality in septic patients (69,70).
The majority of septic patients have coagulation 
abnormalities (71) ranging from subtle not clinical-
ly manifested activation of coagulation to severe 
coagulation disorders such as fulminant form of 
DIC, characterized by simultaneous microvascular 
thrombosis and profuse bleeding from various 
sites thus being a driving force in acute organ dys-
function and death (68,69,71).
The main mechanisms responsible for this severe 
haemostatic disorder in septic patients are medi-
ated by excessive and uncontrolled actions of in-
fl ammatory mediators, in particular, proinfl amma-
tory cytokines. These infl ammatory mediators ac-
tivate coagulation system by TF-mediated path-
way and at the same time signifi cantly downregu-
late physiologic anticoagulant pathways (72). Thus 
the procoagulant activity of the haemostatic sys-
tem exceeds the capacity of the physiologic anti-
coagulants to control the activation of coagula-
tion. Conversely, poorly regulated activity of the 
haemostatic system in turn amplifi es the infl am-
matory process causing additional organ injury.
Additionally, infectious agent itself can cause en-
dothelial damage, which also contributes to the 
prothrombotic state in severe infection. The mod-
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el of endotoxin-induced activation of the haemo-
static system is the best studied model of the com-
plex interactions between infl ammation and hae-
mostasis. Endotoxin is the lipopolysaccharide 
compound from gram negative bacteria responsi-
ble for the severe infection such as sepsis. In blood, 
endotoxin directly binds to CD14 receptor on 
monocytes and binds to ECs after complexing 
with lipopolysaccharide binding protein (LBP) and 
toll-like receptor 4 (TLR-4). Through these interac-
tions, endotoxin induces a number of signalling 
pathways leading to the activation of NF-κB with 
consequent transcription of genes coding a 
number of proinfl ammatory mediators (73). Endo-
toxin also has direct positive eff ect on markedly in-
creased TF expression on infl ammatory cells such 
as leukocytes and ECs.
Further, the fi brinolytic system is directly infl u-
enced by the septic process. In most patients with 
sepsis, fi brinolytic activity is suppressed, while the 
coagulation activation still proceeds. As in other 
infl ammatory states, the main cause of decreased 
fi brinolytic activity in septic patients is increased 
activity of PAI-1 due to sustained actions of proin-
fl ammatory cytokines.
One of the important mechanisms of disturbed 
regulation of the haemostatic system in septic pa-
tients is signifi cantly reduced function of the PC 
system. Clinically, there is a correlation between 
the degree of PC reduction and mortality of septic 
patients (40,74). It has been shown that in patients 
with severe sepsis, the PC system is malfunction-
ing at all levels, including decreased synthesis, in-
creased consumption and degradation and down-
regulation of TM and EPCR at the endothelial sur-
face. Understanding the basic mechanisms of acti-
vation of the haemostatic system and its derange-
ments in sepsis is crucial for the development of 
potential new therapeutic strategies (75). The key 
treatment of patients with sepsis is to treat the un-
derlying infection with appropriate antibiotics and 
additional supportive treatment aimed at circula-
tory and respiratory support. However, abnormali-
ties of the haemostatic system may proceed even 
with proper treatment. In these cases, supportive 
measures to manage haemostatic disorder may be 
considered. Since infl ammation and haemostatic 
system are processes that function in a positive 
feedback loop, it is reasonable to believe that both 
are an appropriate target for intervention to re-
duce mortality in these patients. Improved under-
standing of the molecular mechanisms in the bidi-
rectional interaction between infl ammation and 
haemostasis has led to the development of new 
therapeutic approach for the treatment of severe 
sepsis. Among these agents, recombinant human 
activated protein C (rHuAPC) has shown the most 
promising results by signifi cant reducing mortality 
in patients with severe sepsis (34,76). It is consid-
ered that these benefi cial eff ects of rHuAPC can 
be attributed to anti-infl ammatory properties in 
addition to its anticoagulant activity. However, al-
though therapeutic administration of rHuAPC has 
been advocated in guidelines for the treatment of 
the severe sepsis as an additional treatment strat-
egy (77), there is currently debate on rHuAPC effi  -
cacy since recent fi ndings have cast some doubt 
on its usefulness (78-80).
Conclusion and perspectives
Improved understanding of the molecular mecha-
nisms that play a role in the bidirectional relation-
ship between infl ammation and haemostasis 
could help in the clinical management of patients 
by identifying of new potential therapeutic targets 
that can modify excessive and inappropriate acti-
vation or deregulation of both systems. On the ba-
sis of experimental and clinical studies, it is likely 
that simultaneous modulation of both infl amma-
tory and haemostatic activities, rather than specif-
ic therapy aimed at only one component could be 
more successful in the treatment of clinical states 
and diseases in which close link between infl am-
mation and haemostasis considerably contribute 
to the pathogenesis or progression of disease. 
However, despite the impressive progress in un-
derstanding the molecular mechanisms linking in-
fl ammation and haemostasis during recent years, 
many questions remain open. Therefore, further 
study of the complex molecular mechanisms link-
ing immune and haemostatic systems deserves at-
tention of both medical experts and scientists.
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Upala i hemostaza
Sažetak
Upala i hemostaza su patofi ziološki procesi koji u svom međusobnom odnosu značajno utječu jedan na drugoga. U toj dvosmjernoj vezi upala 
dovodi do aktivacije hemostatskog sustava koji naizmjence također značajno utječe na upalnu aktivnost. Na taj način hemostatski sustav djeluje 
u skladu s upalnom kaskadom stvarajući upalno-hemostatski ciklus u kojem svaki aktivirani proces potiče onaj drugi te oba sustava funkcioniraju 
u petlji pozitivne povratne veze. Opsežna unakrsna komunikacija između imunosnog i hemostatskog sustava događa se na razini svih sastavnica 
hemaostatskog sustava uključujući vaskularne endotelne stanice, trombocite, koagulacijsku kaskadu u plazmi, fi ziološke antikoagulanse i fi bri-
nolitičku aktivnost. Tijekom upalnog odgovora, upalni medijatori, a posebno proupalni citokini, imaju središnju ulogu u utjecajima na hemostat-
ski sustav izazivajući njegov poremećaj u brojnim mehanizmima uključujući disfunkciju endotelnih stanica, povišenu reaktivnost trombocita, 
aktivaciju koagulacijske kaskade u plazmi, oslabljenu funkciju fi zioloških antikoagulansa i potisnutu fi brinolitičku aktivnost. Dva primjera patofi -
zioloških procesa u kojima uska veza između upale i hemostaze značajno pridonosi patogenezi i/ili progresiji bolesti su sustavni upalni odgovor 
na infekciju ili sepsu i akutna arterijska tromboza kao poslijedica pucanja aterosklerotskih naslaga. Bliska povezanost između upale i hemostaze 
pomaže u objašnjenju protrombotske tendencije u ta dva klinička stanja u kojima upala pomiče hemostatsku aktivnost prema prokoagulantnom 
stanju pomoću proupalnih medijatora koji mogu aktivirati koagulacijski sustav i spriječiti antikoagulacijske i fi brinolitičke aktivnosti.
Ovaj pregled nudi sažetak trenutnih spoznaja o kompleksnim interakcijama dvosmjerne veze između upale i hemostaze.
Ključne riječi: upala; hemostaza; upalni medijatori; ateroskleroza; sepsa
